Sumitomo Pharma Co., Ltd. (TYO:4506)
1,565.00
-55.00 (-3.40%)
May 19, 2026, 2:05 PM JST
Sumitomo Pharma Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 106,865 | 23,635 | -314,929 | -96,714 | 40,600 |
Depreciation & Amortization | 20,786 | 25,562 | 37,765 | 41,263 | 38,348 |
Loss (Gain) From Sale of Assets | -49,043 | 5,189 | 180,857 | 75,850 | 769 |
Asset Writedown & Restructuring Costs | 2,073 | - | - | - | - |
Loss (Gain) From Sale of Investments | -3,193 | - | -5,890 | -24,735 | - |
Other Operating Activities | 11,199 | 14,087 | -37,226 | -25,236 | -41,871 |
Change in Accounts Receivable | -50,774 | -909 | 23,390 | 51,218 | -6,097 |
Change in Inventory | 9,005 | 18,837 | -11,795 | 4,560 | 5,356 |
Change in Accounts Payable | 24,431 | -25,868 | 5,645 | 5,318 | -28,669 |
Change in Unearned Revenue | -13,153 | - | - | - | - |
Change in Other Net Operating Assets | 13,519 | -44,033 | -119,710 | -19,587 | 22,803 |
Operating Cash Flow | 71,715 | 16,500 | -241,893 | 11,937 | 31,239 |
Operating Cash Flow Growth | 334.64% | - | - | -61.79% | -76.96% |
Capital Expenditures | -4,609 | -8,498 | -10,771 | -8,467 | -7,347 |
Sale of Property, Plant & Equipment | 449 | 2,208 | 434 | 1,322 | 1,313 |
Cash Acquisitions | -4,008 | - | - | - | - |
Divestitures | 30,477 | 1,458 | 8,605 | 30,172 | - |
Sale (Purchase) of Intangibles | -2,703 | -3,804 | -4,959 | 7,840 | -6,147 |
Investment in Securities | 2,741 | 106,846 | 29,727 | 3,821 | -6,433 |
Other Investing Activities | 202 | 1,544 | - | 2,047 | -797 |
Investing Cash Flow | 22,549 | 99,754 | 33,036 | 52,419 | -18,278 |
Short-Term Debt Issued | - | - | 84,000 | 85,559 | 29 |
Long-Term Debt Issued | - | 139,487 | - | - | - |
Total Debt Issued | - | 139,487 | 84,000 | 85,559 | 29 |
Short-Term Debt Repaid | -4,400 | -181,972 | - | - | - |
Long-Term Debt Repaid | -86,540 | -70,000 | - | -20,060 | -4,960 |
Total Debt Repaid | -90,940 | -251,972 | - | -20,060 | -4,960 |
Net Debt Issued (Repaid) | -90,940 | -112,485 | 84,000 | 65,499 | -4,931 |
Common Dividends Paid | -2 | -3 | -2,792 | -11,125 | -11,126 |
Other Financing Activities | -324 | 3,652 | -3,357 | -201,191 | -5,369 |
Financing Cash Flow | -91,266 | -108,836 | 77,851 | -146,817 | -21,426 |
Foreign Exchange Rate Adjustments | 5,024 | -177 | 15,440 | 24,090 | 17,751 |
Miscellaneous Cash Flow Adjustments | - | -13,172 | 1,135 | -1,135 | - |
Net Cash Flow | 8,022 | -5,931 | -114,431 | -59,506 | 9,286 |
Free Cash Flow | 67,106 | 8,002 | -252,664 | 3,470 | 23,892 |
Free Cash Flow Growth | 738.62% | - | - | -85.48% | -81.56% |
Free Cash Flow Margin | 14.80% | 2.01% | -80.32% | 0.63% | 4.27% |
Free Cash Flow Per Share | 168.91 | 20.14 | -635.97 | 8.73 | 60.14 |
Cash Interest Paid | 4,491 | 4,361 | 3,734 | 2,424 | 2,500 |
Cash Income Tax Paid | 4,564 | -12,182 | 37,595 | 25,450 | 42,331 |
Levered Free Cash Flow | 74,479 | -10,850 | -253,962 | 45,988 | 15,575 |
Unlevered Free Cash Flow | 80,849 | -6,962 | -251,529 | 47,638 | 17,431 |
Change in Working Capital | -16,972 | -51,973 | -102,470 | 41,509 | -6,607 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.